Surgical Menopause: Symptoms, HRT Options, and What to Expect

What surgical menopause is, and how it differs from natural menopause

Surgical menopause, also called induced menopause, is the abrupt and permanent end of ovarian hormone production caused by removing both ovaries (bilateral oophorectomy). It is distinct from natural menopause, which is defined retrospectively after 12 months without a period and is usually preceded by several years of perimenopause, during which estrogen levels fluctuate and gradually decline. It is also distinct from a hysterectomy alone, which removes the uterus but leaves the ovaries in place; a woman who has had only a hysterectomy will not enter surgical menopause, though some evidence suggests she may reach natural menopause somewhat earlier than average, possibly due to changes in ovarian blood supply.

Bilateral oophorectomy is performed for reasons that include ovarian cysts, endometriosis, gynecologic cancer, and risk-reduction surgery in women with BRCA1 or BRCA2 mutations, often alongside a hysterectomy. Because the ovaries are the primary source of estradiol before menopause, removing them causes estradiol to fall from premenopausal levels toward postmenopausal levels within roughly a day, rather than over years. That speed, not a difference in the hormone itself, is what makes surgical menopause generally more abrupt and symptomatic than the natural transition.

The clinically consequential question after bilateral oophorectomy is not simply whether hormone therapy helps menopausal symptoms. For most women under 60 without contraindications, systemic estrogen therapy is the evidence-based default. The harder and more specific question is how urgently to start it, because unlike natural menopause, where estrogen decline is gradual and the body has years to partially adapt, surgical menopause removes that adaptation window in one step, and the associated risks to bone density, cardiovascular health, and mood tracking with untreated estrogen deficiency begin accruing from the day of surgery.

How surgical menopause is diagnosed

When bilateral oophorectomy is documented in the surgical record and symptoms begin within days, the diagnosis is usually clinically obvious. Laboratory testing is still useful to establish a baseline and rule out other causes of overlapping symptoms.

• Follicle-stimulating hormone (FSH) rises sharply once ovarian estradiol no longer suppresses the pituitary. A markedly elevated FSH, drawn several weeks after surgery once acute surgical stress has settled, is consistent with ovarian failure. Exact reference thresholds vary by laboratory and should be interpreted by the ordering clinician.
• Serum estradiol in the postmenopausal range confirms significant estrogen deficiency. Testing too soon after surgery can give a misleading picture because surgical stress affects hormone levels transiently.
• Thyroid function (TSH, free T4) is worth checking at the same visit. Both underactive and overactive thyroid disease can produce fatigue, mood change, and temperature dysregulation that overlaps closely with menopausal symptoms, and untreated thyroid disease is a common reason symptoms fail to improve on hormone therapy alone.

The Menopause Society's 2023 position statement on hormone therapy supports starting hormone therapy in women with premature or early menopause, including surgical menopause, to reduce the excess risks associated with early estrogen loss. The exact wording and scope of that statement should be checked against the Society's current published position when precision matters for an individual patient, since positions are periodically updated.

Why surgical menopause symptoms are often more intense

During natural menopause, estradiol fluctuates and falls over several years, giving the hypothalamus time to partially adjust. In surgical menopause, that adaptation period does not exist. The abrupt loss of estrogen's normal restraint on hypothalamic temperature-regulating neurons is thought to be part of why hot flashes and night sweats can feel more severe and start faster after oophorectomy than during a typical perimenopausal transition. Clinical experience and multiple observational studies describe higher rates of vasomotor symptoms after surgical menopause compared with natural menopause, though exact rate comparisons vary between studies and should not be treated as fixed statistics.

Hot flashes: treatment options and how they compare

Systemic estrogen therapy is the most effective option available for vasomotor symptoms in women without contraindications. Typical delivery routes include:

• Transdermal estradiol (patch or gel), which avoids first-pass liver metabolism and is generally associated with a more favorable clotting and triglyceride profile than oral estrogen in observational cohort data.
• Oral estradiol, which is effective but raises triglycerides and clotting-factor production more than transdermal routes because it passes through the liver first.

Women without a uterus (common after a combined hysterectomy and bilateral oophorectomy) do not need a progestogen, since there is no endometrium to protect from estrogen-driven overgrowth. Women who retain their uterus need a progestogen alongside estrogen to prevent endometrial hyperplasia; the specific agent and dose is an individualized clinical decision.

Fezolinetant (Veozah) is an FDA-approved non-hormonal option (neurokinin-3 receptor antagonist) for moderate-to-severe vasomotor symptoms, approved by the FDA in 2023. It is a reasonable option when estrogen is contraindicated, for example after estrogen-receptor-positive breast cancer. Readers who want the FDA's own summary of the pivotal trial results should consult the agency's drug trial snapshot rather than relying on any single secondary summary, since exact effect sizes are best confirmed from the primary source: FDA Drug Trials Snapshot: Veozah (accessed 2025; regulatory pages are periodically updated, so confirm current status).

Low-dose SSRIs and SNRIs (such as low-dose paroxetine, which has FDA approval specifically for vasomotor symptoms, or off-label venlafaxine and desvenlafaxine) modestly reduce hot flash frequency and are useful when hormone therapy is not appropriate. Paroxetine should generally be avoided in women taking tamoxifen, because it inhibits the enzyme that activates tamoxifen.

Lifestyle measures, including a cooler sleeping environment, layered or moisture-wicking clothing, and limiting alcohol, can reduce trigger frequency but do not address the underlying hormonal mechanism.

Emerging non-traditional estrogens are also in active clinical development for vasomotor symptoms; for example, estetrol is being studied in ongoing randomized trials, described in the published trial design for the E4COMFORT studies (Gaudard 2026). This is trial-stage evidence, not an approved treatment, and should not be treated as a current option.

Vaginal dryness and genitourinary syndrome of menopause (GSM)

GSM describes the cluster of vulvovaginal and urinary symptoms, dryness, burning, painful intercourse, and increased urinary tract infection susceptibility, that result from estrogen-deficiency changes in genital tissue. It is commonly reported by postmenopausal women generally, and reviews of menopause-related sexual health describe genitourinary and sexual symptoms as a frequent, under-discussed part of the menopausal transition (Menopause and Sexual Health: Hormones, Aging or Both?, 2025). After surgical menopause, GSM can appear over weeks rather than the months to years typical of the natural transition, because the drop in estrogen is abrupt.

Treatment options, in order clinicians usually consider them:

• Low-dose vaginal estrogen (cream, insert, or ring) is generally first-line for isolated GSM. Systemic absorption is minimal, which is why professional guidance, including ACOG's guidance on menopausal symptom management, describes it as an option worth discussing even for women with a history of breast cancer, in consultation with their oncologist, when non-hormonal measures have not helped. Exact wording of that guidance should be checked in ACOG's current published bulletin rather than assumed.
• Ospemifene, an oral selective estrogen receptor modulator, is FDA-approved for painful intercourse due to GSM and acts as an estrogen agonist in vaginal tissue.
• Prasterone (vaginal DHEA) is FDA-approved for moderate-to-severe pain with intercourse related to GSM; it is converted locally in vaginal tissue to estrogens and androgens.
• Over-the-counter vaginal moisturizers and lubricants relieve symptoms but do not reverse the underlying tissue changes.

Decision framework: what changes your next step after bilateral oophorectomy

This is a starting point for a conversation with your surgeon or a menopause-trained clinician, not a substitute for one. It organizes the handful of facts that actually change the recommended path.

Bone health after surgical menopause

Estrogen restrains bone breakdown and supports bone-building cells. Multiple observational studies report faster bone density loss in the first several years after bilateral oophorectomy compared with the natural transition, and an association between oophorectomy before roughly age 45 and a higher lifetime hip fracture risk in women who did not use hormone therapy. Exact percentages vary between studies and cohorts, so specific numbers should be checked against current guideline documents rather than treated as fixed.

A baseline bone density (DEXA) scan is reasonable within one to two years of oophorectomy for women who had surgery before age 45, consistent with general endocrinology guidance on early bone loss risk. Systemic estrogen is the most direct way to slow bone loss after oophorectomy; bisphosphonates or denosumab are effective alternatives when estrogen is not an option, and adequate calcium and vitamin D intake support but do not replace either approach.

Cardiovascular risk and the timing of hormone therapy

Estrogen supports blood vessel function and a more favorable cholesterol profile. Multiple observational studies associate bilateral oophorectomy before the typical menopause age with a higher long-term cardiovascular disease risk when hormone therapy is not used, though the size of that association varies across studies and should not be quoted as a single fixed multiplier without checking the specific study population.

Trial evidence, notably the ELITE trial comparing early versus late initiation of estradiol after menopause, supports a "timing hypothesis": estrogen started closer to the onset of menopause appears to have more favorable effects on vascular measures than estrogen started a decade or more later, when no clear benefit was seen. This is trial evidence about vascular surrogate markers, not a guarantee of reduced heart attack or stroke risk for any individual, and the practical takeaway is that the decision to start or defer hormone therapy is time-sensitive rather than open-ended.

Mood, sleep, and cognition

Night sweats fragment sleep, and disrupted sleep independently worsens mood and daytime function regardless of its cause. Observational research associates bilateral oophorectomy, particularly before age 50, with a higher risk of depression compared with women whose ovaries remain intact, and women with a prior history of premenstrual dysphoric disorder or postpartum depression appear more sensitive to the mood effects of rapid estrogen change. A review of menopause and sexual health notes that hormonal change, aging, and psychosocial factors all contribute to mood and sexual symptoms in this life stage, and disentangling how much is hormonal versus situational is not always possible from available evidence (Menopause and Sexual Health: Hormones, Aging or Both?, 2025).

Estrogen therapy improves mood in women whose depressive symptoms are closely tied to vasomotor symptoms and hormonal change. For persistent depression beyond what estrogen resolves, an SSRI or SNRI is a reasonable addition, chosen with attention to interactions such as paroxetine's effect on tamoxifen metabolism.

Testosterone after oophorectomy

The ovaries contribute a substantial share of premenopausal androgen production, so total testosterone typically falls after bilateral oophorectomy. Low testosterone in women is associated with reduced libido and, in some women, fatigue and lower bone and muscle mass, though testosterone's causal contribution to these symptoms individually is harder to isolate than its role in libido.

No testosterone product is currently FDA-approved for women in the United States; use is off-label, typically compounded or a fraction of a male-labeled product dose. International consensus guidance (endorsed by several menopause societies) supports considering testosterone for hypoactive sexual desire disorder in postmenopausal women who are already on systemic estrogen, with monitoring to keep levels within the normal premenopausal female range and avoid androgenic side effects such as acne or excess hair growth. Specific target levels and dosing are individualized decisions between a patient and prescriber, not something to self-determine from population averages.

Choosing a hormone therapy route

Route matters. Transdermal estradiol bypasses first-pass liver metabolism, and observational cohort data generally associate it with a lower risk of blood clots than oral estrogen, though it does not eliminate that risk. For women who had oophorectomy at a young age for cancer risk reduction, including BRCA1 carriers, the risk-benefit calculation for systemic hormone therapy is generally considered favorable by gynecologic oncology and reproductive medicine societies, given that BRCA1-associated breast cancers tend to be estrogen-receptor-negative and the risks of years of untreated estrogen deficiency in a young woman are substantial. This is a decision that should still involve an individualized discussion with the treating oncology and gynecology team.

When to reassess or stop hormone therapy

Most major societies (ACOG, the Menopause Society, and international counterparts) recommend an annual review of hormone therapy that covers symptom control, blood pressure and weight, breast cancer screening status, and bone density monitoring. For women who had surgical menopause before age 45, current guidance generally avoids setting an arbitrary stop date, favoring continued individualized risk-benefit review instead of automatic discontinuation at a fixed age or duration. Anyone considering stopping or continuing therapy long-term should have that conversation directly with their prescriber rather than relying on a general age cutoff.

What is established, what is plausible, and what is not established

Established: bilateral oophorectomy causes an abrupt drop in estradiol and androgens; systemic estrogen therapy relieves vasomotor symptoms and is recommended for most women under 60 without contraindications, especially after early surgical menopause; low-dose vaginal estrogen treats GSM with minimal systemic absorption; fezolinetant, ospemifene, and prasterone are FDA-approved for their specific indications.

Plausible but not settled with precision: the exact magnitude of increased hip fracture and cardiovascular risk after early oophorectomy, the exact comparative duration of vasomotor symptoms in surgical versus natural menopause, and the precise depression risk multiplier associated with oophorectomy. These associations appear in the literature, but specific numbers vary by study population and should be confirmed against current primary sources before being used in any individual risk discussion.

Not established: that any single testosterone target level is universally correct for all women, that a fixed calendar duration of hormone therapy applies to every surgical menopause patient, or that non-hormonal supplements reverse the tissue changes of GSM rather than temporarily relieving symptoms.

When to seek urgent care

Seek prompt medical attention for chest pain, sudden shortness of breath, one-sided leg swelling or pain, sudden severe headache, or new vision or speech changes, whether or not you are on hormone therapy. These are not expected features of surgical menopause and warrant evaluation outside a routine follow-up visit.

References

• FDA Drug Trials Snapshot: Veozah (fezolinetant). U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-veozah
• Gaudard AMIA, et al. Estetrol for the treatment of moderate to severe vasomotor symptoms in postmenopausal women: the design of the E4COMFORT I and II trials (2026). https://pubmed.ncbi.nlm.nih.gov/41289787/
• Menopause and Sexual Health: Hormones, Aging or Both? (2025). https://pubmed.ncbi.nlm.nih.gov/39618033/

A note for the editorial team: several precise statistics in the prior version of this article (mortality figures, fracture-risk multipliers, symptom-duration comparisons, and trial effect sizes) were attached to citations that could not be verified as matching the claim on inspection. Those numbers have been removed or hedged in this draft. Before publication, a clinician reviewer should confirm current figures against the Menopause Society's current position statement, ACOG's current practice guidance, and the primary trial reports for fezolinetant and ospemifene, and reinsert specific numbers only where a verified source directly supports them.